Click' Login' then 'Don't have an Account ' and join $$Lounge for free

Lexaria Corp CSE:LXX OTC:LXRP

More
1 month 5 days ago #121503 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
This looks like a very significant new product

Kelowna, British Columbia / TheNewswire / November 13, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder packet formulation designed to be added to any drink, in any location, creating many innovative-use applications.

Consistent with other Lexaria formulations, ChrgD+ incorporates multi-spectrum hemp oil processed using the Company's patented DehydraTECHTM technology, allowing effective delivery of hemp oil into any existing beverage, hot or cold. At just 2 grams per pouch, ChrgD+ packets can be carried discreetly in a shirt pocket or purse, and consumed anywhere in your preferred soft drink, coffee or energy drink with individual servings. ChrgD+ is nearly flavorless and odorless, offering minimal impact to your already-favorite beverage other than a delightful food-grade pearlescent sparkle effect to remind you that you are getting ChrgD+.

"This new delivery format is truly unique in its performance," said Chris Bunka, CEO of Lexaria Bioscience. "It's a simple way to add a multi spectrum powdered hemp supplement to your favorite beverage at any time and enjoy its fast-acting, non-altered taste with no oily residue. Lexaria's ChrgD+ product format is being evaluated by others for use in their psychoactive cannabinoids products sector as per our proven track record as a technology provider to the industry."

Lexaria engaged Cultivating Wellness Inc, a California-based brand development and distribution company, to create the ChrgD+ premium brand. Cultivating Wellness' distribution network reaches tens of thousands of retail buyers in c-stores, grocery chains, specialty retail, and national accounts.

"Building a brand is just the first step in our relationship," said Lisa Hannah, President of Cultivating Wellness. "Now that ChrgD+ has been launched, we're turning our attention to distributing the product through our growing nationwide distribution network. We are very excited to see how the marketplace responds to this hemp-based wellness product!"

Lexaria's laboratory has incubated several innovative product concepts that leverage the proven performance of the DehydraTECHTM technology, which has received multiple patents for the delivery of both psychoactive and non-psychoactive cannabinoids; nicotine; vitamins, and certain pain relievers.

For information about distributing ChrgD+, email: This email address is being protected from spambots. You need JavaScript enabled to view it..

Come visit Lexaria at the Las Vegas MJBiz Conference November 14-16, booth 3227.

Please Log in or Create an account to join the conversation.

  • Gambler
  • Gambler's Avatar
  • Away
  • Platinum Member
  • Platinum Member
More
1 month 3 weeks ago #121401 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP

Please Log in or Create an account to join the conversation.

More
2 months 10 hours ago #121386 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Still holding long and strong

KELOWNA, BC / ACCESSWIRE / October 18, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has been granted two new US patents.

Lexaria now has six granted patents in the US and four granted patents in Australia. All ten of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof". Specifically, the two new patents are related to certain cannabinoid infused beverage compositions utilizing Lexaria's proprietary DehydraTECHTM process which continue to strengthen the Company's dominant intellectual property in the important cannabis beverage market.

Newly granted patent numbers 10,103,225 and 10,084,044 provide protection for compositions as well as methods for making the compositions, each of which include the use of both non-psychoactive cannabinoids such as CBD and also psychoactive cannabinoids such as THC. Lexaria is currently pursuing accelerated examination for patent applications in Australia based on these newest US patents and hopes to receive two corresponding Australian patents granted by the end of 2018.

With over 50 patent applications filed worldwide across an increasingly diverse range of patent families, Lexaria continues to expand its patent portfolio as a result of positive developments from its many research projects and is currently preparing additional new applications.

Please Log in or Create an account to join the conversation.

More
2 months 1 week ago #121260 by RonS
RonS replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Among World’s Biggest Holders of Cannabis Patents

NEW YORK, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector,” featuring Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP).

To hear the CannabisNewsAudio version, visit: cnw.fm/99vVo

To read the full editorial, visit: cnw.fm/z0TDt

Outside of China, Lexaria is one of the world’s biggest holders of cannabis patents with eight patents already granted. The company currently holds four patents in the United States and four in Australia, covering aspects of its work to make beneficial drugs more palatable and effective. In addition, the company has further patent applications in process in more than 40 countries as part of a concerted strategy to expand its patent portfolio. This is made possible by the focused, tangible research and development being carried out by the company and is ultimately driven by the need to develop and control intangible assets.

Lexaria has disclosed it expects four more patents to be granted in 2018, bringing its total to twelve. Of note, all twelve of these are within a single patent family — and Lexaria expects patent success across all nine families of its current applications. Indeed the company recently revealed that it has seven more patent families in the works. Lexaria’s goal is to have some 200 patents pending or granted which, if achieved, could turn the organization into an IP behemoth in the global cannabis industry.

Please Log in or Create an account to join the conversation.

More
2 months 2 weeks ago #121214 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
SEATTLE, Oct. 03, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. (CSE: LXX) (LXX: CN) (CNSX: LXX) (OTCQX: LXRP). The company has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits.

The cannabis industry is heating up with the legalization of medical and recreational cannabis across Canada and a growing number of states. While cannabis flower has been the early focus, cannabinoid-infused edibles and concentrates represent the fastest growing segments of the $100+ billion industry.

Absorption is one of the most important differentiators for both medical and recreational cannabis products. Medical cannabis patients want to receive a standardized dose and consistent effect each time, while recreational consumers want to experience a high as quickly as possible.

“We are focused on making ingestible or edible bioactive substances taste better, smell better, act faster and enhance potency,” says Lexaria President John Docherty, a trained pharmacologist and toxicologist, who is also the former president and chief operation officer of Helix BioPharma Corp.

Internal R&D vs. Outsourcing

Many cannabis companies plan to launch cannabis-infused products over the coming year. In fact, the alcohol industry has been so concerned about the potential for these products that giants like Constellation Brands Inc. and Molson Coors Brewing Co. have made significant investments.

With the race to develop alternative cannabis products, many cannabis companies have a choice between developing internal delivery platforms or partnering with experts to develop top-performing products. Internal develop involves a high cost and potentially lengthy delays but provides flexibility, while partnerships can provide speed to market and a known solution at a predetermined cost.

Lexaria Biosciences’ innovative drug delivery platform enables cannabis absorption in just 10 to 20 minutes compared to the 60 to 120 minutes for many cannabis edibles on the shelves today. The technology also represents an alternative to sugars and chemicals that are often used to mask flavors. Lexaria was one of the first to offer these solutions to the cannabis industry.

The company has already licensed its products to numerous cannabis companies. For example, the company’s customers include the maker of the 1906 brand of cannabis-infused chocolates in Colorado, a Canadian-based developer of cannabis wines and beers, and a new Canadian company focused on cannabis-infused edibles.

Clinically Proven Advantages

Lexaria’s DehydraTECH platform has shown tremendous promise in several different clinical studies. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the earthy taste of cannabis and delivers it more effectively.

Earlier this year, the company released the results of a randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD—a proprietary DehydraTECH powered CBD hemp oil capsule—showing 317% greater absorption at the 30 minute mark and higher blood concentration. Lexaria is one of very few companies anywhere in the world to have completed human clinical studies related to cannabinoids and have proven that its technology is effective.

The company conducted similar studies of DehydraTECH’s potential with other active ingredients, such as nicotine. In an in-vivo animal study, researchers delivered DehydraTECH powered nicotine in an edible form into blood plasma in just minutes after dosing with 90.2 percent greater delivery than control after just 10 minutes. Lexaria is one of the only companies in the world with technology proven effective in both the nicotine and cannabis industries.

Looking Ahead

Lexaria’s growing portfolio of more than 50 patents has expanded its drug delivery platform well beyond cannabis, including vitamins, NSAIDs, nicotine, and other molecules. Management plans to develop the patent portfolio into 150 to 200 patent applications around the world within two years.

Investors interested in capitalizing on the burgeoning cannabis industry along with additional potential across other multi-billion dollar markets may want to take a closer look at the company ahead of further partnerships and announcements.

For more information, visit the company’s website or download their investor presentation.

Please follow the link to read the full article: www.cannabisfn.com/race-speed-effects-cannabis/

Please Log in or Create an account to join the conversation.

  • Gambler
  • Gambler's Avatar
  • Away
  • Platinum Member
  • Platinum Member
More
2 months 2 weeks ago #121193 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Quite a correction in Pot stocks today, it had to happen

Please Log in or Create an account to join the conversation.

More
2 months 3 weeks ago #121157 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Sector is very frothy, let some of that roll into LXX

Please Log in or Create an account to join the conversation.

  • Gambler
  • Gambler's Avatar
  • Away
  • Platinum Member
  • Platinum Member
More
2 months 4 weeks ago #121133 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP

Please Log in or Create an account to join the conversation.

More
4 months 2 weeks ago #120877 by Hoss
Hoss replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Very Positive news today

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBDTM - a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria. The degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers were studied.

Key bioavailability data highlights from the study comparing the 90 mg dose of Lexaria's TurboCBD™ to a 90 mg dose of a positive control formulation without Lexaria's DehydraTECH™ technology were as follows:

30 Minutes: CBD delivered from Lexaria's TurboCBDTM capsules was absorbed much more effectively than from the positive control, delivering 317% more CBD to blood at the 30-minute mark of the study (i.e., 18.4 ng/mL compared to only 4.4 ng/mL on average respectively [95% CI; p=0.051]);
60 Minutes: The TurboCBDTM capsules went on to deliver more CBD to the blood at the 60-minute mark (i.e., 38.8 ng/mL) than the positive control capsules were able to reach at any time during the 6-hour study, further demonstrating the exceptional rapidity of action and effectiveness of the TurboCBD™ capsules;
90 Minutes: The TurboCBDTM capsules further went on to deliver significantly more CBD to the blood (86% more) than the positive control capsules at the 90-minute mark (i.e., 53.0 ng/mL compared to only 28.4 ng/mL respectively [95% CI; p=0.034]);
Through to Study Completion: Lexaria's TurboCBDTM capsules continued to deliver more CBD to blood than the positive control capsules at each subsequent time point in the study through to the 6-hour mark when the study was completed.

These results corroborate and confirm earlier in vitro and in vivo studies that have evaluated Lexaria's DehydraTECHTM technology and have consistently measured higher levels of drug delivery much more quickly than positive controls with matching CBD concentrations. Although this study evaluated absorption only of CBD and its metabolites, Lexaria believes nearly identical bioavailability enhancement results would be achieved if the cannabinoid studied was THC instead of CBD.

Please Log in or Create an account to join the conversation.

More
6 months 9 hours ago #120757 by RonS
RonS replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Yes, stock is on the verge of a breakout

Please Log in or Create an account to join the conversation.

More
6 months 3 days ago #120742 by DearJohn
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
I am holding, this is going to break out to the upside. Can feel it, Pot is where all the action has been

Please Log in or Create an account to join the conversation.

  • Gambler
  • Gambler's Avatar
  • Away
  • Platinum Member
  • Platinum Member
More
6 months 4 days ago #120728 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
stock still trying to make that break out. I am cheering

Please Log in or Create an account to join the conversation.

Time to create page: 0.262 seconds

Login Form